

IACH 2022 Preliminary Timetable
All timing in CEST

Thursday, September 22, 2022	
13:00-13:10	Welcome: Mohamad Mohty , France & Arnon Nagler , Israel
13:10-15:00	Session 1 – Plenary Opening
13:10-13:30	A revolution in ultra-rare diseases: the example of BPDCN: Naveen Pemmaraju , USA
13:30-13:50	How I choose the optimal conditioning for AML: Arnon Nagler , Israel
13:50-14:10	How I treat sickle cell anemia: Adetola Kassim , USA
14:10-14:30	Clinical implications of novel genomic discoveries in CLL: Catherine Wu , USA
14:30-15:00	Panel Discussion
15:00-16:50	Session 2 – AML
15:00-15:20	How I treat newly diagnosed AML: Jordi Sierra , Spain
15:20-15:40	How I treat relapsed AML: Christoph Schmid , Germany
15:40-16:00	How I use targeted agents as a maintenance therapy in AML: Tapan Kadia , USA
16:00-16:20	Disease monitoring in AML: Christopher Hourigan , USA
16:20-16:50	Panel Discussion
16:50-18:40	Session 3 – ALL
16:50-17:10	How I treat newly diagnosed ALL: Sebastian Giebel , Poland
17:10-17:30	How I treat relapsed ALL (excluding CAR T therapy): Elias Jabbour , USA
17:30-17:50	CAR T therapy in relapsed ALL: Eolia Brissot , France
17:50-18:10	Disease monitoring in ALL: <i>TBA</i>
18:10-18:40	Panel Discussion
18:40-19:30	IACH H.J. Khoury Award Ceremony Presenters: Mohamad Mohty , France & Arnon Nagler , Israel
18:40-18:55	<i>Award presentation</i>
18:55-19:30	Keynote lecture I: TBA

Friday, September 23, 2022	
11:00-12:50	Session 4 – Multiple myeloma
11:00-11:20	Diagnostic work-up of myeloma: <i>TBA</i>
11:20-11:40	Inductions regimens in myeloma: Philippe Moreau , France
11:40-12:00	Management of relapsed/ refractory myeloma (excluding CAR T): Maria Victoria Mateos , Spain
12:00-12:20	CAR T therapy in relapsed/ refractory myeloma: Mohamad Mohty , France
12:20-12:50	Panel Discussion
12:50-14:40	Session 5 – Lymphomas
12:50-13:10	How I treat high grade B cell lymphomas: Christian Gisselbrecht , France
13:10-13:30	How I treat low grade B cell lymphomas: Olivier Hermine , France
13:30-13:50	How I treat Hodgkin Lymphomas: Anna Sureda , Spain
13:50-14:10	How I treat T cell lymphomas: Ali Bazarbachi , Lebanon
14:10-14:40	Panel Discussion
14:40-16:10	Industry symposium
16:10-18:00	Session 6 – Transplant
16:10-16:30	How I prevent relapses after transplant in AML/ MDS: Bipin Savani , USA
16:30-16:50	Metabolic complications in hematological cancer survivors: Brian Engelhardt , USA
16:50-17:10	Endothelial complications after HCT: Nelson Chao , USA
17:10-17:30	Revised post-transplant vaccinations guidelines after transplant: Per Ljungman , Sweden
17:30-18:00	Panel Discussion
18:00-19:30	Industry symposium

19:30-21:20	Session 7 – Chronic leukemia
19:30-19:50	How I diagnose CLL: Robin Foà , Italy
19:50-20:10	How I treat CLL: Arnon Kater , Netherlands
20:10-20:30	How I treat CML: Giuseppe Saglio , Italy
20:30-20:50	Role of CAR T therapy in CLL: Mohamad Kharfan-Dabaja , USA
20:50-21:20	Panel Discussion

Saturday, September 24, 2022

11:00-12:50	Session 8 – MDS/ MPD
11:00-11:20	How I classify MDS: Valeria Santini , Italy
11:20-11:40	Novel approaches to transplant management of MF: Tania Jain , USA
11:40-12:00	How I treat MDS- non- transplant management: Amer Zeidan , USA
12:00-12:20	How I treat MDS- transplant management: Ibrahim Yakoub-Agha , France
12:20-12:50	Panel Discussion
12:50-14:20	Industry symposium
14:20-16:10	Session 9 – Marrow failure syndrome
14:20-14:40	How I treat aplastic anemia: Phillip Scheinberg , Brazil
14:40-15:00	How I treat sickle cell anemia: TBA
15:00-15:20	How I treat hypoplastic MDS: Yogen Sauntharajah , USA
15:20-15:40	How I treat large granular lymphocytic leukemia: Jaroslawn Maciejewski , USA
15:40-16:10	Panel Discussion
16:10-16:40	Keynote lecture II: TBA
16:40-16:45	Closing remarks: Mohamad Mohty , France & Arnon Nagler , Israel